Abstract 1290TiP
Background
Adjuvant (adj) or neoadjuvant (neoadj) immunotherapy has been recently approved for the treatment of resectable early stage Non-Small Cell Lung Cancer (NSCLC), and further advances are needed. The combination of neoadj Durvalumab (D), an anti-PD-L1, combined with chemotherapy (CT) and adj D (AEGEAN) in early-stage NSCLC has recently demonstrated promising safety and efficacy. CD39 is an extracellular ectonucleotidase highly expressed in the tumor microenvironment (TME) that, sequentially with CD73, contributes to the production of adenosine (Ado), via hydrolysis of Ado triphosphate (ATP). IPH5201 is a blocking anti-CD39 monoclonal antibody that may promote antitumor immunity by accumulating immunostimulatory ATP released by CT-treated tumor cells and reducing immunosuppressive Ado levels in the TME. Moreover, IPH5201 improved the efficacy of CT+D in preclinical models. In a phase 1, IPH5201 + D was well tolerated and pharmacodynamically active.
Trial design
MATISSE is a phase II multicenter (France, Poland, Greece, Hungary, USA), single arm study (NCT05742607) sponsored by Innate Pharma, evaluating IPH5201 + D + CT in treatment-naive pts with resectable (stage II to IIIA) NSCLC. Up to 70 pts will receive neoadj IPH5201 + D in addition to platinum-doublet CT for 4 cycles followed by surgery within 40 days. Pts will thereafter receive adj IPH5201+D every 4 weeks for up to 12 cycles post-surgery or until recurrence or unacceptable toxicity. The primary objectives are to assess antitumor activity of neoadj treatment based on pathological complete response (pCR) and safety. The secondary objectives are to assess efficacy in terms of event free survival, disease free survival, feasibility of receiving the planned surgery, major pathological response, objective response rate, overall survival, pharmacokinetics and immunogenicity. Assessment of exploratory biomarkers is also planned. A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed.
Clinical trial identification
IND:162253; NCT05742607; EudraCT: 2022-001903-42.
Editorial acknowledgement
Legal entity responsible for the study
Innate Pharma.
Funding
Innate Pharma.
Disclosure
F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. O. Mercier: Financial Interests, Personal, Advisory Board, Board on surgical oncology (lung cancer): AstraZeneca; Financial Interests, Personal, Advisory Board, Board for CTEPH (non cancer related): MSD; Financial Interests, Institutional, Funding, Paceport Study investigator (non cancer related) Study on pulmonary hemodynamics: Edwards Lifesciences. A. Łowczak, S. Mandziuk, J. Kuzdzal, A. Dasgupta: Non-Financial Interests, Institutional, Principal Investigator: Innate. A. Koutras: Financial Interests, Personal, Advisory Board: Pierre Fabre, AstraZeneca, Gilead, Pfizer, Genesis, MSD, BMS; Financial Interests, Personal, Invited Speaker: Sanofi, Gilead; Financial Interests, Personal, Other, Travel, Accommodations: Rafarm, Lilly, Ipsen, Gilead, Pfizer; Financial Interests, Institutional, Funding: Lilly, Pfizer, Merck; Financial Interests, Institutional, Research Grant: AstraZeneca, Pierre Fabre, BMS, Demo, Faran, Amgen, Roche, Ipsen, Galenica, Win Medica. A.J. Leyco, P. Andre, C.L. Paturel, A. Boyer Chammard: Financial Interests, Institutional, Full or part-time Employment: Innate. R. Mager, P.G. Fraenkel: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca.
Resources from the same session
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04